US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $65.00 price target on Structure Therapeutics (NASDAQ:GPCR) stock Monday. According to InvestingPro data, the stock currently trades at $21.73, with analyst targets ranging from $37.50 to $120, reflecting significant potential upside. The company, valued at $1.25 billion, typically moves counter to broader market trends with a beta of -1.97.
The research firm cited recent Phase 3 ACHIEVE-1 trial data for Eli Lilly (NYSE:LLY)’s oral GLP-1 receptor agonist orforglipron presented at the American Diabetes Association (ADA) conference. Cantor Fitzgerald noted these results have implications for Structure Therapeutics’ aleniglipron due to similarities in scaffold and chemical structure between the two compounds. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 23.29 and more cash than debt on its balance sheet.
The detailed safety data for orforglipron, which Cantor Fitzgerald described as "solid with not much to nitpick," was a key focus of the presentation. The efficacy data, previously released, showed weight loss and HbA1c reduction comparable to injectable semaglutide.
Cantor Fitzgerald indicated the positive safety profile of orforglipron suggests "an extremely low probability of any off-target effects/liver safety issues with aleniglipron" for Structure Therapeutics.
Structure Therapeutics is expected to release Phase 2B obesity data for aleniglipron by the end of 2025. The company’s next earnings report is scheduled for August 7, 2025. For deeper insights into Structure Therapeutics’ financial health and growth prospects, including additional ProTips and comprehensive analysis, check out the full research report available on InvestingPro.
In other recent news, Structure Therapeutics has been the focus of several analyst reports highlighting its ongoing clinical trials and potential market impact. H.C. Wainwright reiterated its Buy rating with a price target of $75, noting the promising data from the ACHIEVE-1 trial presented at the American Diabetes Association Conference. The trial results suggest that oral drugs like Structure’s aleniglipron could become significant in diabetes treatment. Meanwhile, JMP Securities maintained a Market Outperform rating with an $89 price target, emphasizing the upcoming Phase 2b data for aleniglipron as a potential turning point for the company. Citi analysts initiated coverage with a Buy rating and a $60 target, citing the potential of Structure’s lead drug candidate and diverse pipeline, especially in the obesity treatment market.
Additionally, H.C. Wainwright reaffirmed its Buy rating and increased the price target to $80, highlighting the advantages of aleniglipron’s safety profile over competitors. Analysts at JMP reiterated a Market Outperform rating with an $87 target, focusing on the anticipated data for orforglipron and its implications for weight loss in both diabetic and non-diabetic individuals. The absence of safety issues in upcoming trials is seen as a potential positive catalyst for Structure Therapeutics’ shares. These developments underscore the company’s strategic position in the oral GLP-1 agonist market and its potential to influence future treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.